Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design
Details
Publication Year 2022-02,Volume 18,Issue #4,Page 425-436
Journal Title
Future Oncology
Publication Type
Protocol
Abstract
PARP inhibitors in combination with androgen receptor-targeted therapy have demonstrated potential in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here, we describe the design and rationale of the multinational, phase III, two-part TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide as a first-line treatment for patients with mCRPC with or without DNA damage response (DDR) alterations. This study has two co-primary end points: radiographic progression-free survival (rPFS) by blinded independent clinical review in all-comers (cohort 1) and in patients with DDR alterations (cohort 2). TALAPRO-2 will demonstrate whether talazoparib plus enzalutamide can significantly improve the efficacy of enzalutamide in terms of rPFS in both molecularly unselected and DDR-deficient patients with mCRPC (NCT03395197). Clinical Trial Registration: NCT03395197 (ClinicalTrials.gov).
Keywords
Androgen Receptor Antagonists/therapeutic use; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Benzamides/*therapeutic use; DNA Damage/drug effects/genetics; Humans; Male; Neoplasm Metastasis; Nitriles/*therapeutic use; Phenylthiohydantoin/*therapeutic use; Phthalazines/*therapeutic use; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant/*drug therapy/pathology; Ddr; PARP inhibitor; androgen receptor; enzalutamide; mCRPC; talazoparib
Department(s)
Medical Oncology
PubMed ID
35080190
Open Access at Publisher's Site
https://doi.org/10.2217/fon-2021-0811
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-25 04:53:31
Last Modified: 2024-09-25 05:00:19

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙